| According
to the Attention Deficit Disorder (ADD) Information Center, 3% to
10% of the U.S. population is affected with ADD and its many forms
(ADHD/LD). As a result, an estimated 20 million children may be placed
on activity-modifying drugs like Methlyphenidate before the year 2000.
Attention
deficit disorder drugs have been suspected of retarding growth of
attention deficit individuals, which ironically is the last thing
you would want to do with individuals who have been neurally limited!
Amphetamines, antidepressants or anticonvulsants normally prescribed
for ADD have been shown to detrimentally diminish cognitive activity
and exhibit harmful side effects, such as nervousness, insomnia
and anorexia.
Attention
Deficit is big business in the U.S. where therapies for ADD/ADHD
have reached $2 billion. In Europe, Attention Deficit diagnosis
is only one-tenth as common as it is in the U.S., and in Japan,
the disorder has barely been noted. Consumption of the mood-altering
drug Methlyphenidate in the U.S. versus the rest of the world has
become so disparate that the Vienna-based International Narcotics
Control Board has asked American authorities to monitor it to be
certain it is being properly prescribed.
View
a list of common side effect associated with popular ADD/ADHD drugs
Learn
about an all natural alternative for attention deficit disorder
|